Medifron DBT Co. Ltd Total Assets
Medifron DBT Co. Ltd total assets. Based on the latest financial reports, Medifron DBT Co. Ltd (065650) holds total assets worth ₩113.62 Billion KRW (≈ $77.00 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 065650 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Medifron DBT Co. Ltd (2014–2024)
Total assets of Medifron DBT Co. Ltd from 2014 to 2024. This chart illustrates how Medifron DBT Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Medifron DBT Co. Ltd stock quote for real-time trading data and today's change.
Medifron DBT Co. Ltd - Asset Composition Analysis
Medifron DBT Co. Ltd Total Assets Breakdown (December 2024)
Medifron DBT Co. Ltd total assets breakdown as of December 2024. Medifron DBT Co. Ltd's total assets of ₩113.62 Billion consist of 42.4% current assets and 57.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩7.62 Billion | 0.0% |
| Accounts Receivable | ₩11.86 Billion | 19.6% |
| Inventory | ₩1.44 Billion | 2.4% |
| Property, Plant & Equipment | ₩7.91 Billion | 13.1% |
| Intangible Assets | ₩130.75 Million | 0.2% |
| Goodwill | ₩6.99 Billion | 11.6% |
Asset Composition Trend (2014–2024)
This chart illustrates how Medifron DBT Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Medifron DBT Co. Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medifron DBT Co. Ltd's current assets represent 42.4% of total assets in 2024, an increase from 19.3% in 2014.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 1.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 79.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 19.6% of total assets.
Medifron DBT Co. Ltd Competitors by Total Assets
Key competitors of Medifron DBT Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Medifron DBT Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.01 | 1.47 | 1.29 |
| Quick Ratio | 0.96 | 1.42 | 1.03 |
| Cash Ratio | 0.00 | 0.45 | 0.00 |
| Working Capital | ₩1.15 Billion | ₩16.03 Billion | ₩5.01 Billion |
Medifron DBT Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Medifron DBT Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.89 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.3% |
| Total Assets | ₩60.40 Billion |
| Market Capitalization | $12.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medifron DBT Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Medifron DBT Co. Ltd's assets grew by 8.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Medifron DBT Co. Ltd (2014–2024)
The table below shows the annual total assets of Medifron DBT Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩60.40 Billion ≈ $40.94 Million |
+8.28% |
| 2023-12-31 | ₩55.79 Billion ≈ $37.81 Million |
+0.06% |
| 2022-12-31 | ₩55.75 Billion ≈ $37.78 Million |
+13.56% |
| 2021-12-31 | ₩49.10 Billion ≈ $33.27 Million |
+3.98% |
| 2020-12-31 | ₩47.22 Billion ≈ $32.00 Million |
+142.64% |
| 2019-12-31 | ₩19.46 Billion ≈ $13.19 Million |
-9.79% |
| 2018-12-31 | ₩21.57 Billion ≈ $14.62 Million |
-17.81% |
| 2017-12-31 | ₩26.24 Billion ≈ $17.78 Million |
-5.44% |
| 2016-12-31 | ₩27.75 Billion ≈ $18.81 Million |
-10.01% |
| 2015-12-31 | ₩30.84 Billion ≈ $20.90 Million |
+16.45% |
| 2014-12-31 | ₩26.48 Billion ≈ $17.95 Million |
-- |
About Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more